Radiotherapy Center Cluj S.R.L. — Clinical Trial Site

99 Registered trials

40 Currently recruiting

Organisation

Radiotherapy Center Cluj S.R.L.

Location

Floresti, Romania

Identifier

ORG-100041797

Address

Strada Oitelor 7, 040278, Romania

Departments

040005: Oncology
2304:Oncology
3203: Oncology
3203:oncology
40004: Oncology
6101: Oncology
6103:Oncology
93150001: Oncology
Departament Clinic Oncologie Medicala
Departament Oncologie Medicala
Medical Oncology
Medical Oncology Department
N/A
NA
Oncologie
Oncologie Medicală
Oncologie Medicala - Radioterapie
Oncology
Radiology Center
ROU005: Oncology
Sectia Oncologie Medicala
Specialitatea Oncologie Medicala

Clinical trials at this site (99)

Search interface

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 EGFR-mutated Non-small Cell Lung Cancer 10
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting

2025-523586-18-00 Non-Small Cell Lung Cancer 5 2026-06-11
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting

2025-523263-37-00 Previously Untreated Advanced or Metastatic Gastric, Ga 10 2026-04-08
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26